Emmanuel Antonarakis: Most compelling study suggesting that combined Abiraterone and Olaparib is better than sequential Abiraterone and Olaparib for 1st-line mCRPC
Emmanuel Antonarakis, Professor of Medicine at the University of Minnesota, shared a post on X about his recent paper, commenting:
“BRCAaway: Most compelling study suggesting that combined Abiraterone and Olaparib is better than sequential Abiraterone and Olaparib or Olaparib and Abiraterone for BRCA and ATM-altered 1st-line Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Congratulations to Maha Hussain, The Prostate Cancer Clinical Trials Consortium (PCCTC), Neeraj Agarwal, Arul Chinnaiyan, Zachery Reichert, Leonidas Platanias.”
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) published in AACR Journals.
Authors: Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault-Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel Shevrin, Travis Gerke, Arul M. Chinnaiyan, Emmanuel S. Antonarakis.
Yüksel Ürün reshared the post by Emmanuel Antonarakis on X:
“Congratulations Emmanuel Antonarakis et al. Clinically very relevant question!
HRR mutations affect ~25% of Metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. The BRCAAway trial found Abiraterone or Prednisone and Olaparib combination significantly improves Progression-Free Survival (PFS) over single agents in those with BRCA1/2 or ATM mutations!”
Additional information
Source: Emmanuel Antonarakis/X and Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023